Physician profile
Dara Adames
NPI 1336795913
$1,529.50
in general payments reported to CMS, 2019-2025
10 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $55.01 · 2023: $400 · 2024: $371 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,005.86 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $205.74 | 2021-2024 | Qulipta |
| Exact Sciences Corporation | $86.57 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $66.61 | 2021-2023 | |
| Lilly USA, LLC | $49.85 | 2022-2024 | Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $37.05 | 2024 | Farxiga |
| Horizon Therapeutics Plc | $29.12 | 2021 | |
| Merck Sharp & Dohme LLC | $19.45 | 2021 | |
| Alkermes, INC. | $17.98 | 2021 | |
| Indivior INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Adames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.